Alliance to drive greater efficiencies across clinical trials in oncology and hematology
BOSTON and OSAKA, August 21, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients.
“Oncology continues to be the largest therapeutic area in clinical trials today, and is a priority for PAREXEL as we partner with clients to deliver new therapies to patients in need,” said Shogo Nakamori, Corporate Vice President, Clinical Research Services, Asia Pacific, PAREXEL. “Osaka International Cancer Institute is a center of excellence for clinical trials in the Kansai region of Japan. Through this alliance, PAREXEL and the Osaka International Cancer Institute will work to drive greater efficiencies for local and global biopharmaceutical companies, helping them accelerate the clinical development of innovative and effective new treatments in this difficult disease area.”
“The advancement of clinical trials in oncology is imperative in the development of promising new therapies for patients in Japan and around the world,” said Dr. Nariaki Matsuura, President of Osaka International Cancer Institute. “We are pleased to be working with PAREXEL, an innovative partner with a large presence in Japan, and globally, with leading clinical and scientific expertise in oncology. Through this collaboration, Osaka International Cancer Institute will gain access to novel treatments sooner, providing a wider range of potential treatment options for our patients and allowing us to make a strong contribution to the further advancement of cancer treatments.”
PAREXEL established operations in Japan in 1995 and has more than 1,300 employees based in Tokyo, Kobe, and Osaka. PAREXEL is a leading provider of biopharmaceutical services in the Asia-Pacific region, helping clients design drug development programs and conduct studies regionally and internationally. Over the last five years alone, PAREXEL has led more than 2,300 oncology projects in over 1.2 million patients across nearly 78,000 sites worldwide.
About Osaka International Cancer Institute
The Osaka International Cancer Institute was established in September 1959 as the Osaka Prefectural Lifestyle Related Disease Center. In March 2017 it was renamed the Osaka International Cancer Institute and relocated to its current location. The Center consists of the hospital division, the research division, and the cancer control center. The hospital was the first public hospital in Japan to be certified as an advanced treatment hospital and retains this honor to date. Among the top hospitals in the country, the Osaka International Cancer Institute provides various treatment options, including surgery, chemotherapy, radiotherapy, and immunotherapy treatments. The hospital has a high level of technical expertise and experience in treating cancer, specializing in refractory cancers, such as pancreatic cancer. The research division has its own cancer cell processing/culture method, CTOS/iCC, for the development of new cancer treatments, and the cancer control center serves as an advisor on public policies for cancer control to Osaka Prefecture, leveraging cancer registry data. Together the three divisions provide education and treatment for patients with cancer.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #
Tel.: +81 3-5543-9500
Tel.: +1 781-434-4772
Tel.: +1 781-434-4753
Osaka International Cancer Institute Contact:
Hiroshi Yamasaki, Public Relations
Tel.: +81 6-6945-1181